281 related articles for article (PubMed ID: 21840056)
1. Economic burden associated with patients diagnosed with hepatitis C.
McCombs JS; Yuan Y; Shin J; Saab S
Clin Ther; 2011 Sep; 33(9):1268-80. PubMed ID: 21840056
[TBL] [Abstract][Full Text] [Related]
2. Cost-effectiveness of peginterferon alfa-2a (40kDa) plus ribavirin in patients with HIV and hepatitis C virus co-infection.
Hornberger J; Torriani FJ; Dieterich DT; Bräu N; Sulkowski MS; Torres MR; Green J; Patel K
J Clin Virol; 2006 Aug; 36(4):283-91. PubMed ID: 16765638
[TBL] [Abstract][Full Text] [Related]
3. Peginterferon alfa-2a versus peginterferon alfa-2b as initial treatment of hepatitis C virus infection: a cost-utility analysis from the perspective of the Veterans Affairs Health Care System.
Yeh WS; Armstrong EP; Skrepnek GH; Malone DC
Pharmacotherapy; 2007 Jun; 27(6):813-24. PubMed ID: 17542764
[TBL] [Abstract][Full Text] [Related]
4. Pharmacoeconomic analysis of the treatment of chronic hepatitis C with peginterferon alfa-2a or peginterferon alfa-2b plus ribavirin in Spain.
Turnes J; Romero-Gómez M; Planas R; Solà R; García-Samaniego J; Diago M; Crespo J; Calleja JL; Rubio-Terrés C; Ventayol P
Gastroenterol Hepatol; 2013 Nov; 36(9):555-64. PubMed ID: 24119723
[TBL] [Abstract][Full Text] [Related]
5. Cost-effectiveness of treatment for chronic hepatitis C infection in an evolving patient population.
Salomon JA; Weinstein MC; Hammitt JK; Goldie SJ
JAMA; 2003 Jul; 290(2):228-37. PubMed ID: 12851278
[TBL] [Abstract][Full Text] [Related]
6. [Cost-utility analysis of triple therapy with telaprevir in treatment-naïve hepatitis C patients].
Buti M; Gros B; Oyagüez I; Andrade RJ; Serra MA; Turnes J; Casado MA
Farm Hosp; 2014 Sep; 38(5):418-29. PubMed ID: 25344136
[TBL] [Abstract][Full Text] [Related]
7. Direct medical care costs among pegylated interferon plus ribavirin-treated and untreated chronic hepatitis C patients.
Solomon M; Bonafede M; Pan K; Wilson K; Beam C; Chakravarti P; Spiegel B
Dig Dis Sci; 2011 Oct; 56(10):3024-31. PubMed ID: 21717127
[TBL] [Abstract][Full Text] [Related]
8. Cost-effectiveness analysis of boceprevir for the treatment of chronic hepatitis C virus genotype 1 infection in Portugal.
Elbasha EH; Chhatwal J; Ferrante SA; El Khoury AC; Laires PA
Appl Health Econ Health Policy; 2013 Feb; 11(1):65-78. PubMed ID: 23355388
[TBL] [Abstract][Full Text] [Related]
9. Economic evaluation of early monotherapy versus delayed monotherapy or combination therapy in patients with acute hepatitis C in Germany.
Dintsios CM; Haverkamp A; Wiegand J; Gerlach T; Wedemeyer H; Pape G; Manns MP; Krauth C
Eur J Gastroenterol Hepatol; 2010 Mar; 22(3):278-88. PubMed ID: 19550347
[TBL] [Abstract][Full Text] [Related]
10. Impact of hepatitis C triple therapy availability upon the number of patients to be treated and associated costs in France: a model-based analysis.
Deuffic-Burban S; Mathurin P; Pol S; Larsen C; Roudot-Thoraval F; Desenclos JC; Dhumeaux D; Yazdanpanah Y
Gut; 2012 Feb; 61(2):290-6. PubMed ID: 21930731
[TBL] [Abstract][Full Text] [Related]
11. A multidisciplinary support programme increases the efficiency of pegylated interferon alfa-2a and ribavirin in hepatitis C.
Carrión JA; Gonzalez-Colominas E; García-Retortillo M; Cañete N; Cirera I; Coll S; Giménez MD; Márquez C; Martin-Escudero V; Castellví P; Navinés R; Castaño JR; Galeras JA; Salas E; Bory F; Martín-Santos R; Solà R
J Hepatol; 2013 Nov; 59(5):926-33. PubMed ID: 23811030
[TBL] [Abstract][Full Text] [Related]
12. Pharmacoeconomic analysis of treatment of patients infected with hepatitis C virus.
Qureshi S; Qazi MH; Aziz MT
Pak J Pharm Sci; 2018 Mar; 31(2):365-369. PubMed ID: 29618422
[TBL] [Abstract][Full Text] [Related]
13. Cost-effectiveness of boceprevir co-administration versus pegylated interferon-α2b and ribavirin only for patients with hepatitis C genotype 1 in Singapore.
Dan YY; Ferrante SA; Elbasha EH; Hsu TY
Antivir Ther; 2015; 20(2):209-16. PubMed ID: 25105844
[TBL] [Abstract][Full Text] [Related]
14. The impact of lifetime alcohol use on hepatitis C treatment outcomes in privately insured members of an integrated health care plan.
Russell M; Pauly MP; Moore CD; Chia C; Dorrell J; Cunanan RJ; Witt G; Martin S
Hepatology; 2012 Oct; 56(4):1223-30. PubMed ID: 22488513
[TBL] [Abstract][Full Text] [Related]
15. Cost-effectiveness of telaprevir in combination with pegylated interferon alpha and ribavirin in previously untreated chronic hepatitis C genotype 1 patients.
Cure S; Bianic F; Gavart S; Curtis S; Lee S; Dusheiko G
J Med Econ; 2014 Jan; 17(1):65-76. PubMed ID: 24160335
[TBL] [Abstract][Full Text] [Related]
16. Treatment patterns and adherence among patients with chronic hepatitis C virus in a US managed care population.
Mitra D; Davis KL; Beam C; Medjedovic J; Rustgi V
Value Health; 2010; 13(4):479-86. PubMed ID: 20102555
[TBL] [Abstract][Full Text] [Related]
17. Antiviral treatment for hepatitis C virus infection is associated with improved renal and cardiovascular outcomes in diabetic patients.
Hsu YC; Lin JT; Ho HJ; Kao YH; Huang YT; Hsiao NW; Wu MS; Liu YY; Wu CY
Hepatology; 2014 Apr; 59(4):1293-302. PubMed ID: 24122848
[TBL] [Abstract][Full Text] [Related]
18. Cost effectiveness evaluation of hepatitis C therapy in Lahore.
David YJ; Tahir A; Riaz M
Pak J Pharm Sci; 2017 Nov; 30(6):2233-2237. PubMed ID: 29175794
[TBL] [Abstract][Full Text] [Related]
19. Cost-effectiveness of treatment for hepatitis C in an urban cohort co-infected with HIV.
Campos NG; Salomon JA; Servoss JC; Nunes DP; Samet JH; Freedberg KA; Goldie SJ
Am J Med; 2007 Mar; 120(3):272-9. PubMed ID: 17349451
[TBL] [Abstract][Full Text] [Related]
20. Cost-effectiveness of telaprevir in combination with pegylated interferon alpha and ribavirin in treatment-experienced chronic hepatitis C genotype 1 patients.
Cure S; Bianic F; Gavart S; Curtis S; Lee S; Dusheiko G
J Med Econ; 2014 Jan; 17(1):77-87. PubMed ID: 24032626
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]